UK information session for Swiss medtech companies
The UK’s Department for International Trade in Switzerland announced a virtual information session specially for Swiss medtech and medical device companies, to give an update on latest policy developments and regulatory guidance. The event will take place online on Monday, 16 November 2020, 15:00 – 16:30 CET.
Among others, the session will focus on the consequences of Brexit on policies and regulatory landscape as well as the agreements UK-CH.
If you are Swiss manufacturer and you need any assistance regarding how to place or continue to market your device in the UK after Brexit, contact Meditrial today!
Meditrial is an international reknowed CRO headquarted in Switzerland with branches in the EU and US, and extensive knowledge of the regulatory and clinical environment in Switzerland and the UK. Reach out to us today and be the first to comply!
Meditrial can help – find out more!
More about the event held by the UK’s Department for International Trade
Contact Meditrial for immediate assistance in Europe or the US.
Table of Contents
Build a Defensible Clinical Evidence Strategy Under EU MDR
Build a defensible clinical evidence strategy under MDR Annex XIV, from the clinical evaluation plan to PMCF and notified body review.
Getting a CE mark for medical devices: a step-by-step guide
Practical guidance on the CE mark for medical devices under EU MDR, from classification and evidence to conformity assessment and EUDAMED
A Practical RBQM Framework for Medical Device Trials
Risk-based quality management for medical device trials, with practical actions for risk assessment, monitoring, data review, and trial oversight
EU Breakthrough Medical Devices Under MDCG 2025-9 (BtX)
EU breakthrough medical devices gain a clearer regulatory pathway under MDCG 2025-9, with early advice and lifecycle evidence planning
What Swissmedic Fast-Track Means for Clinical Trial Sponsors
Swissmedic swissethics Fast-Track Pilot Project accelerates eligible trial reviews and makes coordinated regulatory preparation increasingly important.
FDA Breakthrough Device Acceleration
How innovative MedTech companies can accelerate FDA approval, secure Medicare coverage, and reach patients faster—starting with Breakthrough Device Designation.
This article provides general information and does not constitute regulatory or legal advice. Requirements should be confirmed for the specific study, applicable regulatory framework, and markets concerned.
